Ocular Therapeutix, Inc.

NASDAQ:OCUL

Biotechnology

Healthcare
$5.94 -1.17%

-$0.11 today

Market cap
$1.31B
Beta
0.90
P/E (TTM)
-7.3
EPS (TTM)
-$1.30
52W Low $6.23High $16.44

Volume 3.67M

Average 3.00M

OCUL Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Ocular Therapeutix, Inc.NASDAQ: OCUL

Net Receivables · Q1 FY2026 · quarter ended Mar 2026

Net receivables falls 3.5% from a year ago

Net receivables stood at $24.35M at the end of Q1 FY2026, down 3.5% from a year earlier and down 20.6% from the prior quarter. Over 3 fiscal years it compounded at +12.9% a year.

Context

  • Net receivables amounted to 3.3% of total assets at the end of Q1 FY2026, down 2.9 pp from a year earlier.
  • Net receivables increased in 2 of the last 3 fiscal years.

What to watch

Whether net receivables keeps falling in the next quarterly balance sheet after a -3.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$24.35M-20.6% QoQ
Last fiscal yearDec 2025
$30.65M-5.4% YoY
Year agoMar 2025
$25.22M-3.5% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-3.5%——
1 year-5.4%——
3-year CAGR+12.9%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
30.65M USD
Year-over-year change
-5.4%
4-year CAGR
+9.7%

Net Receivables vs competitors

How OCUL compares with its peers on the latest reported figures

  • Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
  • Its year-over-year change of -3.5% is the 6th highest of 7, against a peer median of +49.2%.
  • Net receivables amounts to 3.3% of total assets for OCUL, versus a peer median of 4.5%.
OCUL Competitors
Net Receivables for OCUL and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
BLCOBausch + Lomb CorporationJun 2026$1.16B USD+6.6%+18.9%8.4%
GKOSGlaukos CorporationJun 2026$138.9M USD+67.4%+44.4%15.1%
HROWHarrow Health, Inc.Mar 2026$101.26M USD+31.0%+158.9%24.1%
STAASTAAR Surgical CompanyApr 2026$85.69M USD+100.7%-6.1%19.0%
OCULOcular Therapeutix, Inc.Mar 2026$24.35M USD-3.5%+12.9%3.3%
OTLKOutlook Therapeutics, Inc.Mar 2026$2.72M USD——12.4%
OCSOculis Holding AGMar 2026CHF 1.57M CHF-38.7%—0.6%
EYPTEyePoint Pharmaceuticals, Inc.Mar 2026$1.16M USD+161.8%-65.2%0.4%
SGPSpyGlass Pharma, Inc. Common StockMar 2026$653K USD——0.3%
KODKodiak Sciences Inc.Sep 2026$0 USD——0.0%
OCGNOcugen, Inc.Mar 2026$0 USD——0.0%
Peer median (excluding OCUL) —+49.2%+18.9%4.5%

Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents164.16M102.3M195.81M392.1M737.06M
Short-term Investments00000
Net Receivables21.14M21.33M26.18M32.39M30.65M
Inventory1.25M1.97M2.31M3.04M3.56M
Other Current Assets04.03M7.94M13.46M10.86M
Total Current Assets191.3M129.63M232.24M440.99M782.13M
Property, Plant & Equipment (Net)11.82M17.9M18.21M15.33M24.31M
Goodwill00000
Intangible Assets00000
Long-term Investments00001.61M
Tax Assets00000
Other Non-current Assets1.76M1.76M1.61M1.61M0
Total Non-current Assets13.59M19.66M19.83M16.95M25.93M
Total Assets204.89M149.29M252.06M457.94M808.06M
Account Payables4.59M5.12M4.39M4.18M4.15M
Short-term Debt00002.82M
Tax Payables00000
Deferred Revenue0576K255K128K0
Other Current Liabilities000025.86M
Total Current Liabilities26.34M31.4M34.9M41.35M50.81M
Long-term Debt51.44M54.01M74.93M68.51M74.15M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)13M13.39M14.14M14M14M
Other Non-current Liabilities20.19M6.44M30.1M13.39M11.98M
Total Non-current Liabilities90.55M82.52M126.03M101.24M102.94M
Total Liabilities116.89M113.91M160.93M142.59M153.75M
Common Stock8K8K12K16K22K
Retained Earnings(545.8M)(616.84M)(697.58M)(891.08M)(1.16B)
Accumulated OCI00000
Other Stockholders Equity00000
Minority Interest00000
Total Equity88M35.38M91.13M315.34M654.31M
Total Debt58.98M64.28M83.39M75.78M79.78M
Net Debt(105.18M)(38.02M)(112.42M)(316.32M)(657.28M)

Ocular Therapeutix, Inc.

NASDAQ:OCUL

Intrinsic Alpha fair value

Locked

Current Price

$5.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.